Please login to the form below

Not currently logged in
Email:
Password:

Fabry disease

This page shows the latest Fabry disease news and features for those working in and with pharma, biotech and healthcare.

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Fabry disease is a rare disorder in which patients inherit a deficiency of the α–Galactosidase–A enzyme. ... Fabry disease is a rare inherited disorder. Patients inherit a deficiency of the α–Galactosidase–A enzyme that results in the breakdown

Latest news

More from news
Approximately 5 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • The trials and tribulations of rare opportunities The trials and tribulations of rare opportunities

    Revenue for Fabrazyme for treating Fabry disease, which affects 5, 000 people worldwide, was $891m. ... Patient-centricity is also core to Pfizer’s rare disease recruitment strategy, said Brownrigg.

  • Pharma deals in August 2015 Pharma deals in August 2015

    380 which will be used to treat cachexia, a wasting disease seen in cancer patients. ... Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Firstly, GSK decided to return rights to the experimental Fabry disease drug migalastat, noting that support would continue through GSK's equity investment of $3m. ... The deal gives Amicus access to Callidus' late-stage enzyme replacement therapy for

  • Payer focus in the personalised world of oncology and orphan diseases Payer focus in the personalised world of oncology and orphan diseases

    Personalised medicine is transforming disease understanding and many traditional diagnoses may be fundamentally revised based on the new scientific understanding. ... The Netherlands recently tried to withdraw public funding for late onset Fabry Disease

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Sobi names Holly May VP of sales and marketing, US Sobi names Holly May VP of sales and marketing, US

    Rare disease firm Sobi has appointed Holly May as its new vice president of sales and marketing for the US. ... May has had more than 20 years’ experience in biopharmaceutical sales and marketing, with her most recent role serving as head of US

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Focus on Rare Diseases

    As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond. ... Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....